Literature DB >> 34498068

The Effect of Scheduled Intravenous Acetaminophen in an Enhanced Recovery Protocol Pathway in Patients Undergoing Major Abdominal Procedures: A Prospective, Randomized, and Placebo-Controlled Clinical Trial.

Kathirvel Subramaniam1, Stephen A Esper1, Kushanth Mallikarjun2, Alec Dickson1, Kristin Ruppert DrPH3, Tomas Drabek1, Hesper Wong1, Jennifer Holder-Murray4.   

Abstract

OBJECTIVE: Enhanced recovery protocols (ERPs) utilize multi-modal analgesia regimens. Individual regimen components should be evaluated for their analgesic efficacy. We evaluated the effect of scheduled intravenous (IV) acetaminophen within an ERP on analgesia and recovery after a major abdominal surgery.
DESIGN: This study is a prospective, randomized, double-blinded clinical trial.
SETTING: The study setting was a tertiary care, academic medical center.
SUBJECTS: Adult patients scheduled for elective major abdominal surgical procedures.
METHODS: Patients in group A received 1 g IV acetaminophen, while patients in group P received IV placebo every six hours for 48 hours postoperatively within an ERP. Pain scores, opioid requirements, nausea and vomiting, time to oral intake and mobilization, length of stay, and patient satisfaction scores were measured and compared.
RESULTS: From 412 patients screened, 154 patients completed the study (Group A: 76, Group P: 78). Primary outcome was the number of patients with unsatisfactory pain relief, defined as a composite of average Numeric Rating Scale (NRS) scores above 5 and requirement of IV patient-controlled analgesia for pain relief during the first 48 hours postoperatively, and was not significantly different between the two groups (33 (43.4%) in group A versus 42 (53.8%) patients in group P, P = .20). Opioid consumption was comparable between two groups. Group A utilized significantly less postoperative rescue antiemetics compared to group P (41% vs. 58%, P = .02).
CONCLUSIONS: Scheduled administration of IV acetaminophen did not improve postoperative analgesia or characteristics of postoperative recovery in patients undergoing major abdominal surgery within an ERP pathway.
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Abdominal Surgery; Acetaminophen; Enhanced Recovery; Multimodal Analgesia; Postoperative Analgesia

Mesh:

Substances:

Year:  2022        PMID: 34498068      PMCID: PMC9019635          DOI: 10.1093/pm/pnab272

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.637


  31 in total

1.  Comparison of CAM-ICU and ICDSC for the detection of delirium in critically ill patients focusing on relevant clinical outcomes.

Authors:  Cristiane Damiani Tomasi; Carmen Grandi; Jorge Salluh; Márcio Soares; Vinícius Renê Giombelli; Sarah Cascaes; Roberta Candal Macedo; Larissa de Souza Constantino; Daiane Biff; Cristiane Ritter; Felipe Dal Pizzol
Journal:  J Crit Care       Date:  2011-07-06       Impact factor: 3.425

2.  Intravenous administration of propacetamol reduces morphine consumption after spinal fusion surgery.

Authors:  J Hernández-Palazón; J A Tortosa; J F Martínez-Lage; D Pérez-Flores
Journal:  Anesth Analg       Date:  2001-06       Impact factor: 5.108

3.  Randomized trial of oral versus intravenous acetaminophen for postoperative pain control.

Authors:  Skip R Hickman; Kathleen M Mathieson; Lynne M Bradford; Casey D Garman; Richard W Gregg; Douglas W Lukens
Journal:  Am J Health Syst Pharm       Date:  2018-03-15       Impact factor: 2.637

4.  A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.

Authors:  Steven J Wininger; Howard Miller; Harold S Minkowitz; Mike A Royal; Robert Y Ang; James B Breitmeyer; Neil K Singla
Journal:  Clin Ther       Date:  2010-12       Impact factor: 3.393

Review 5.  Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials.

Authors:  C Remy; E Marret; F Bonnet
Journal:  Br J Anaesth       Date:  2005-01-28       Impact factor: 9.166

6.  Intravenous Acetaminophen in Multimodal Pain Management for Patients Undergoing Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Minako Murata-Ooiwa; Sachiyuki Tsukada; Motohiro Wakui
Journal:  J Arthroplasty       Date:  2017-05-15       Impact factor: 4.757

7.  Decreased opioid consumption and enhance recovery with the addition of IV Acetaminophen in colorectal patients: a prospective, multi-institutional, randomized, double-blinded, placebo-controlled study (DOCIVA study).

Authors:  Amir H Aryaie; Sepehr Lalezari; Wallace K Sergent; Yana Puckett; Christopher Juergens; Craig Ratermann; Cari Ogg
Journal:  Surg Endosc       Date:  2018-01-19       Impact factor: 4.584

8.  Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery beyond triple prophylaxis.

Authors:  P Ziemann-Gimmel; A A Goldfarb; J Koppman; R T Marema
Journal:  Br J Anaesth       Date:  2014-02-18       Impact factor: 9.166

Review 9.  Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.

Authors:  Tong J Gan; Kumar G Belani; Sergio Bergese; Frances Chung; Pierre Diemunsch; Ashraf S Habib; Zhaosheng Jin; Anthony L Kovac; Tricia A Meyer; Richard D Urman; Christian C Apfel; Sabry Ayad; Linda Beagley; Keith Candiotti; Marina Englesakis; Traci L Hedrick; Peter Kranke; Samuel Lee; Daniel Lipman; Harold S Minkowitz; John Morton; Beverly K Philip
Journal:  Anesth Analg       Date:  2020-08       Impact factor: 5.108

10.  Hospitalization costs and resource allocation in cholecystectomy with use of intravenous versus oral acetaminophen.

Authors:  Ryan N Hansen; An T Pham; Elaine A Böing; Belinda Lovelace; George J Wan; Donna A Thomas; Manuel L Fontes
Journal:  Curr Med Res Opin       Date:  2018-01-04       Impact factor: 2.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.